Law360, New York (May 21, 2009, 12:00 AM ET) -- A federal court has allowed an investor class action alleging that Dendreon Corp. and its officers deceived investors about the approval process for its experimental advanced prostate cancer drug Provenge to continue.
The U.S. District Court for the Western District of Washington on Thursday denied a motion to dismiss most claims of the suit against Dendreon, its CEO Mitchell Gold and its Chief Science Officer David Urdal. However, the court did dismiss claims against Urdal under Section 10(b) of the Securities Exchange Act.
The order did...
Investor Suit Against Dendreon Can Proceed
To view the full article, take a free trial now.
